CD8A and neoplasm: Consistent with the previous results, the highest levels of activated CD8+ T cells in the tumor and spleen (Fig. 8e, j) and IFN-γ secretion (Fig. 8f, k) were observed in 4T1 tumors treated with iGel and αPD-L1 and in TC1 tumors treated with iGel and αPD-1, respectively.